Cargando…

Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias

SIMPLE SUMMARY: Chimeric antigen receptors (CAR) can redirect the activity of NK cells to target T-cell malignancies. Our results identify that recognition of CD5 molecules in malignant T cells by the CAR leads to improved antitumor response compared to targeting CD3, due to strong downregulation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voynova, Elisaveta, Hawk, Nga, Flomerfelt, Francis A., Telford, William G., Gress, Ronald E., Kanakry, Jennifer A., Kovalovsky, Damian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833462/ https://www.ncbi.nlm.nih.gov/pubmed/35158792 http://dx.doi.org/10.3390/cancers14030524

Ejemplares similares

From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
por: Voynova, Elisaveta, et al.
Publicado: (2021)

Siglec-6 is a Target for Chimeric Antigen Receptor T-cell Treatment of Chronic Lymphocytic Leukemia
por: Kovalovsky, Damian, et al.
Publicado: (2021)

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

A Soluble NK-CAR Mediates the Specific Cytotoxicity of NK Cells toward the Target CD20(+) Lymphoma Cells
por: Liu, Rongjiao, et al.
Publicado: (2022)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

The Increased Ratio of Blood CD56(bright) NK to CD56(dim) NK Is a Distinguishing Feature of Primary Sjögren's Syndrome
por: Ming, Bingxia, et al.
Publicado: (2020)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
por: Althaus, Jonas, et al.
Publicado: (2023)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Reduction of the CD16(−)CD56(bright) NK Cell Subset Precedes NK Cell Dysfunction in Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells
por: Salman, Huda, et al.
Publicado: (2019)

Requirement for CD40/CD40L Interactions for Development of Autoimmunity Differs Depending on Specific Checkpoint and Costimulatory Pathways
por: Voynova, Elisaveta, et al.
Publicado: (2018)

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
por: Liu, Tingdang, et al.
Publicado: (2023)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
por: Gurney, Mark, et al.
Publicado: (2021)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
por: Liao, Chan, et al.
Publicado: (2023)

CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity
por: Husak, Z, et al.
Publicado: (2012)

TREM2 promotes natural killer cell development in CD3(−)CD122(+)NK1.1(+) pNK cells
por: Lee, Hwa-Youn, et al.
Publicado: (2021)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

CD56(neg)CD16(+) NK cells are activated mature NK cells with impaired effector function during HIV-1 infection
por: Milush, Jeffrey M, et al.
Publicado: (2013)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia
por: Yao, Danlin, et al.
Publicado: (2020)

NK Cells Regulate CD8(+) T Cell Mediated Autoimmunity
por: Lang, Philipp A., et al.
Publicado: (2020)

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020)

A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers
por: Dehbashi, Moein, et al.
Publicado: (2021)

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
por: Caruso, Simona, et al.
Publicado: (2022)

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
por: Li, Hongwen, et al.
Publicado: (2023)

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
por: Ciulean, Ioana Sonya, et al.
Publicado: (2023)

Aggressive NK-Cell Leukemia
por: Ishida, Fumihiro
Publicado: (2018)

Liver-infiltrating CD11b(−)CD27(−) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression
por: Zhang, Qiong-Fang, et al.
Publicado: (2017)

CAR NK Cell Therapy for T Follicular Helper Cells
por: King, Cecile
Publicado: (2020)

Current Progress of CAR-NK Therapy in Cancer Treatment
por: Pang, Zhaojun, et al.
Publicado: (2022)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nlora3smlhj00bdufqap9qn7qs